In studies in real life, concerning the efficacy of anti-IL-5 drugs, regardless of the number of eosinophils, provided that above 300 cells/μl, B-EOS correlated with risk of asthma exacerbations, the decline in respiratory function, mortality, and systemic corticosteroid dependence (44). Here, IL5 is linked to asthma.